Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
Authors
Keywords
-
Journal
Alzheimers & Dementia
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-02-11
DOI
10.1002/alz.12302
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Amyloid β-protein and beyond: the path forward in Alzheimer’s disease
- (2020) Dominic M Walsh et al. CURRENT OPINION IN NEUROBIOLOGY
- Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation
- (2020) Erik C. B. Johnson et al. NATURE MEDICINE
- The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates
- (2020) Aladdin Riad et al. MOLECULAR NEUROBIOLOGY
- Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
- (2020) Colleen S. Limegrover et al. JOURNAL OF NEUROCHEMISTRY
- Proceedings from the Fourth International Symposium on sigma-2 Receptors: Role in Health and Disease
- (2020) Nicholas J. Izzo et al. eNeuro
- Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid
- (2019) Alberto Lleó et al. MOLECULAR & CELLULAR PROTEOMICS
- Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease
- (2019) Nicolas R. Barthélemy et al. Frontiers in Aging Neuroscience
- Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes
- (2019) Halley M. Oyer et al. Frontiers in Pharmacology
- Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
- (2018) Erik Portelius et al. ACTA NEUROPATHOLOGICA
- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
- (2018) Christopher H. van Dyck BIOLOGICAL PSYCHIATRY
- Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study
- (2018) Eline A.J. Willemse et al. CLINICAL CHEMISTRY
- Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead
- (2018) Devendra Kumar et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer’s Disease
- (2018) Elizabeth C. Mormino et al. JOURNAL OF ALZHEIMERS DISEASE
- Let-7i inhibition enhances progesterone-induced functional recovery in a mouse model of ischemia
- (2018) Trinh Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex
- (2018) Aladdin Riad et al. Scientific Reports
- Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease
- (2017) Bitna Yi et al. JOURNAL OF NEUROCHEMISTRY
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- Cdc42 and Rac1 activity is reduced in human pheochromocytoma and correlates with FARP1 and ARHGEF1 expression
- (2016) Pauline Croisé et al. ENDOCRINE-RELATED CANCER
- Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates
- (2016) Claire L. Russell et al. JOURNAL OF ALZHEIMERS DISEASE
- Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease
- (2016) Chang Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer’s mouse model
- (2016) Carla M. Yuede et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate
- (2016) Ting Yang et al. JOURNAL OF NEUROSCIENCE
- Alzheimer's disease
- (2016) Philip Scheltens et al. LANCET
- Increased CSF neurogranin concentration is specific to Alzheimer disease
- (2016) Henrietta Wellington et al. NEUROLOGY
- Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study
- (2016) Claire L. Russell et al. RAPID COMMUNICATIONS IN MASS SPECTROMETRY
- Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice
- (2016) Arne Ittner et al. SCIENCE
- The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
- (2016) Annika Öhrfelt et al. Alzheimers Research & Therapy
- Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
- (2016) Rawan Tarawneh et al. JAMA Neurology
- Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
- (2015) Kirsten L. Viola et al. ACTA NEUROPATHOLOGICA
- Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
- (2015) Erik Portelius et al. BRAIN
- Protective alleles and modifier variants in human health and disease
- (2015) Andrew R. Harper et al. NATURE REVIEWS GENETICS
- Neurogranin Levels in Cerebrospinal Fluid
- (2015) Henrik Zetterberg et al. JAMA Neurology
- SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
- (2014) Ann Brinkmalm et al. Molecular Neurodegeneration
- Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy
- (2014) Natalia Crespo-Biel et al. NEUROBIOLOGY OF DISEASE
- Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity
- (2014) Nicholas J. Izzo et al. PLoS One
- Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits
- (2014) Nicholas J. Izzo et al. PLoS One
- Regulation of transcription factor activity by interconnected post-translational modifications
- (2014) Theresa M. Filtz et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- GSK-3β, a pivotal kinase in Alzheimer disease
- (2014) MarÃa Llorens-MarÃtin et al. Frontiers in Molecular Neuroscience
- Global Analysis of Phosphorylation of Tau by the Checkpoint Kinases Chk1 and Chk2 in vitro
- (2013) Jhoana Mendoza et al. JOURNAL OF PROTEOME RESEARCH
- The CAMKK2-AMPK Kinase Pathway Mediates the Synaptotoxic Effects of Aβ Oligomers through Tau Phosphorylation
- (2013) Georges Mairet-Coello et al. NEURON
- Human LilrB2 Is a -Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model
- (2013) T. Kim et al. SCIENCE
- Neuropathological Alterations in Alzheimer Disease
- (2013) A. Serrano-Pozo et al. Cold Spring Harbor Perspectives in Medicine
- The Importance of Tau Phosphorylation for Neurodegenerative Diseases
- (2013) Wendy Noble et al. Frontiers in Neurology
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
- (2012) Robert M. Koffie et al. BRAIN
- The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain
- (2012) Jessica M. McDonald et al. BRAIN RESEARCH
- Progesterone Increases the Release of Brain-Derived Neurotrophic Factor from Glia via Progesterone Receptor Membrane Component 1 (Pgrmc1)-Dependent ERK5 Signaling
- (2012) Chang Su et al. ENDOCRINOLOGY
- S2RPgrmc1: the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling
- (2012) Ikhlas S A Ahmed et al. Expert Opinion on Drug Metabolism & Toxicology
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- Thy1-hAPPLond/Swe+mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function
- (2012) Mehrdad Faizi et al. Brain and Behavior
- Binding of amyloid β peptide to β2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity
- (2010) Dayong Wang et al. FASEB JOURNAL
- Picomolar Amyloid- Positively Modulates Synaptic Plasticity and Memory in Hippocampus
- (2009) D. Puzzo et al. JOURNAL OF NEUROSCIENCE
- Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake
- (2009) Shaomin Li et al. NEURON
- Oligomeric amyloid associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
- (2009) R. M. Koffie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Amyloid Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization
- (2008) I. Klyubin et al. JOURNAL OF NEUROSCIENCE
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
- (2008) Ganesh M Shankar et al. NATURE MEDICINE
- Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies
- (2003) Mary P. Lambert et al. JOURNAL OF NEUROCHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started